绥美凯北京买的到吗？

On January 20, 2018, ViiV, a joint venture company under GlaxoSmithKline (hereinafter referred to as GSK), the first complete antiviral treatment regimen drug with dolutegravir (also known as DTG in English) as the core, was officially launched in China. This is also the first complete single-pill compound treatment regimen in the field of HIV treatment in China. Soon after, not only patients in Beijing, but also patients in mainland China could purchase Suimeikan in hospitals. 

Currently, there are more than 40 HIV antiviral treatment drugs in the world. However, due to various reasons, there are only 7 drugs in my country's free drug list. In addition, some drugs can be obtained at one's own expense. However, because they are not included in the medical insurance list, the price is generally relatively expensive, and the choice of treatment options is very limited. The newly released Suimeikai three-in-one treatment is currently not included in the scope of free drugs, and the market price is 2880$/month. Although this treatment is the only three-in-one compound single-dose drug currently on the market in China and has many advantages, no drug is perfect. It is worth mentioning here that this treatment contains abacavir (ABC), which may cause hypersensitivity reactions. If you are currently using free drugs and have good tolerance, it is recommended not to consider replacing such self-paid drugs for the time being. Of course, this type of drug has an additional option for those who have the financial ability and need to replace it. According to GSK's recommendations, patients who are new to treatment (have not received HARRT treatment before), whose viral load before treatment is less than 100,000, who cannot tolerate the neurological adverse reactions caused by efavirenz (EVF), and whose financial conditions permit, may consider choosing Suimeikai, but they must consult a professional doctor before treatment. It is worth mentioning that Inbec, produced by the Indian company Emcure, comes in a box of 30 tablets and sells for about RMB 1,000. If patients choose this highly cost-effective product, they can go to India to buy it in person, but it is best to obtain it through domestic professional overseas medical service institutions.